Last reviewed · How we verify
Warfarin and Enoxaparin
Warfarin inhibits vitamin K-dependent clotting factors while enoxaparin is a low-molecular-weight heparin that enhances antithrombin activity to prevent blood clot formation.
Warfarin inhibits vitamin K-dependent clotting factors while enoxaparin is a low-molecular-weight heparin that enhances antithrombin activity to prevent blood clot formation. Used for Venous thromboembolism (DVT/PE) prevention and treatment, Atrial fibrillation with stroke risk, Mechanical heart valve thromboprophylaxis.
At a glance
| Generic name | Warfarin and Enoxaparin |
|---|---|
| Also known as | Coumadin |
| Sponsor | Cook County Health |
| Drug class | Anticoagulant combination (vitamin K antagonist + low-molecular-weight heparin) |
| Target | Vitamin K-dependent clotting factors (warfarin); Factor Xa and Factor IIa (enoxaparin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Warfarin works by antagonizing vitamin K, thereby reducing synthesis of clotting factors II, VII, IX, and X in the liver. Enoxaparin potentiates antithrombin III's inhibition of factors Xa and IIa, providing rapid anticoagulation. Together, they provide both immediate (enoxaparin) and sustained (warfarin) anticoagulation, often used during warfarin initiation to bridge therapy.
Approved indications
- Venous thromboembolism (DVT/PE) prevention and treatment
- Atrial fibrillation with stroke risk
- Mechanical heart valve thromboprophylaxis
- Acute coronary syndrome
Common side effects
- Bleeding (major and minor)
- Heparin-induced thrombocytopenia (HIT)
- Injection site reactions (enoxaparin)
- Elevated liver enzymes
- Skin necrosis (warfarin)
Key clinical trials
- Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) (PHASE3)
- Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula (NA)
- Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer (NA)
- Study of Rivaroxaban for CeREbral Venous Thrombosis (PHASE2)
- A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation (PHASE2)
- Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices
- Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease (PHASE3)
- Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Warfarin and Enoxaparin CI brief — competitive landscape report
- Warfarin and Enoxaparin updates RSS · CI watch RSS
- Cook County Health portfolio CI